Comorbidity and depression treatment

Biological Psychiatry

Volumn 53, Issue 8, 2003, Pages 701-706

  Krishnan, K Ranga Rama ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anxiety; Comorbidity; Medical; Personality; Response; Treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DISEASE SEVERITY; DOSE RESPONSE; ELECTROCONVULSIVE THERAPY; HEALTH STATUS; HUMAN; MAJOR DEPRESSION; PERSONALITY DISORDER; PREDICTION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PERSONALITY DISORDERS;

EID: 0038147545     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01787-0     Document Type: Review

References (33)

1. Bielski RJ, Friedel RO (1976): Prediction of tricyclic antidepressant response: A critical review. Arch Gen Psychiatry 33:1479-1489.
2. Fava M, Bouffides E, Pava JA, McCarthy MK, Steingard RJ, Rosenbaum JF (1994): Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychother Psychosom 62:160-167.
3. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Koop JB, Nilsson ME (2000): Fluoxetine versus sertraline and paroxetine in major depression: Tolerability and efficacy in anxious depression. Affect Disord 59:119-126.
4. Fawcett J, Barkin RE (1998): A meta-analysis of eight randomized double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 59:123-127.
5. Feske U, Frank E, Kupfer DJ, Shear MK, Weaver E (1998): Anxiety as a predictor of response to interpersonal psychotherapy for recurrent major depression: An exploratory investigation. Depress Anxiety 8:135-141.
6. Gaynes BN, Magruder KM, Burns BJ, Wagner HR, Yarnall KS, Broadhead WE (1999): Does a coexisting anxiety disorder predict persistance of depressive illness in primary care patients with major depression? Gen Hosp Psychiatry 21(3): 158-167.
7. George EK, Blazer DG, Hughes DC, Fowler N (1989): Social support and the outcome of major depression. Br J Psychiatry 154:478-485.
8. Gill D, Hatcher S (2000): Antidepressants for depression in medical illness. Cochrane Database Syst Rev. (4):CD001312.
9. Hirschfeld RM, Russell JM, Delgado PL, Fawcett J, Friedman RA, Harrison WM, et al (1998): Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 59:669-675.
10. Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, et al (2000): Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 57:76-82.
11. Joyce PR, Mulder RT, Cloninger CR (1994): Temperament predicts clomipramine and desipramine response in major depression. J Affect Disord 30:35-46.
12. Koenig HG, Goli V, Shelp F, Kudler HS, Cohen HJ, Meador KG, Blazer DG (1989): Antidepressant use in elderly medical inpatients: Lesions from an attempted clinical trial. J Gen Intern Med 4:498-505.
13. Krishnan KR, Doraiswamy PM, Clary CM (2001): Clinical and treatment response characteristics of late-life depression associated with vascular disease: A pooled analysis of two multicenter trials with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 25:347-361.
14. Landerman R, George LK, Campbell RT, Blazer DG (1989): Alternative models of the stress buffering hypothesis. Am J Community Psychol 17:626-642.
15. Linn BS, Linn MW, Gurel L (1968): Cumulative illness rating scale. J Am Geriatr Soc 16:622-626.
16. Montgomery SA, Asberg M (1979): A new rating scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
17. Mulder RT (2002): Personality pathology and treatment outcome in major depression: A review. Am J Psychiatry 159:359-371.
18. Nelson L, Cloninger CR (1997): Lxploring the TPQ as a possible predictor of antidepressant response to nefzaodone in a large multi-site study. J Affect Dis 44:197-200.
19. Newman JR, Ewing SE, McColl RD, Boras JS, Nierenberg AA, Pava J, Fava M (2000): Tridemensional Personality Questionnaire and treatment response in major depressive disorder: a negative study. J Affect Dis 57:241-247.
20. Paykel ES (1972): Depressive typologies and response to amitriptyline. Br J Psychiatry 120:147-156.
21. Peselow LD, Fieve RR, DiFiglia C (1992): Personality traits and response to desipramine. J Affect Disord 24:209-216.
22. Popkin MK, Callies AL, Mackenzie TB (1985): The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 42:1160-1163.
23. Radloff LS (1977): The CLS-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1:385-401.
24. Robins LN, Helzer JE, Croughan J, Ratcliff KS (1981): National Institute of Mental Health Diagnostic Interview Schedule: Its history, characteristics, and validity. Arch Gen Psychiatry 38:381-389.
25. Rudolph RL, Entsuah R, Chitra R (1998): A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 18:136-144.
26. Russell JM, Koran LM, Rush J, Hirschfeld RM, Harrison W, Friedman ES, et al (2001): Lffect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 13:18-27.
27. Sato T, Sakado K, Sato S (1993): Is there any specific personality disorder or personality disorder cluster that worsens the short-term treatment outcome of major depression? Acta Psychiatr Scand 88:342-349.
28. Silverstone PH, Saunas E (2001): Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 62:523-529.
29. Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M (1999): Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry 60(9):580-583.
30. Steffens DC, Doraiswamy PM, McQuoid DR (2001): Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry 16:862-865.
31. Steffens DC, McQuoid DR, Krishnan KRR (2002): The Duke somatic treatment algorithm for geriatric depression (STAGED) approach. Psychopharm Bull 36:58-68.
32. Tollefson GD, Holman SL, Sayler ME, Potvin JH (1994): Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 55:50-59.
33. Zimmerman M, Chelminski I, McDermut W (2002): Major depressive disorder and Axis I diagnostic comorbidity. J Clin Psychiatry 63:187-193.